HUMANOO

HUMANOO Competitive Intelligence & Landscape

humanoo.com ·

Overview

HUMANOO Overview

HUMANOO is a digital health platform founded in 2016 and headquartered in Berlin, Germany. The company specializes in providing health and well-being solutions for employees and insurance policyholders, focusing on improving physical and mental health through personalized programs (crunchbase, pitchbook). Its core products include cloud-based platforms offering fitness coaching, yoga, nutrition, and mental health programs designed to promote healthier lifestyles and increase productivity (mountain-partners, css). The company's target market primarily comprises organizations seeking to enhance employee well-being and reduce healthcare costs, with a focus on behavioral change and digital health management (linkedin, tracxn). HUMANOO aims to empower individuals and organizations to lead healthier lives through innovative eHealth solutions and customized health programs, positioning itself as a leader in digital health innovation (readkong).

Competitors

HUMANOO Competitors

Deep Care is a notable competitor to HUMANOO, primarily focusing on digital health and wellness solutions that include personalized care plans and health management tools. It differentiates itself with a strong emphasis on AI-driven health insights and integration with healthcare providers, aiming to enhance patient engagement and outcomes (CB Insights). In terms of market positioning, Deep Care targets healthcare organizations and insurers, offering a more clinical approach compared to HUMANOO's broader employee wellness focus.

Uplyfe is another key competitor, known for its comprehensive employee wellness platforms that combine mental health, physical activity, and nutrition programs. Uplyfe’s strength lies in its user-friendly interface and customizable wellness programs, which appeal to corporate clients seeking tailored solutions. Compared to HUMANOO, Uplyfe often offers more flexible pricing models and a wider array of integrated health services, aiming to capture a larger share of the corporate wellness market (CB Insights).

RAYNY distinguishes itself with a focus on holistic health management, integrating mental health, physical activity, and nutritional support into a unified platform. Its market positioning is geared toward both individual consumers and corporate clients, emphasizing mental well-being and stress reduction. RAYNY’s features often include advanced analytics and personalized coaching, positioning it as a more technologically sophisticated alternative to HUMANOO, with competitive pricing and a growing user base (CB Insights).

Billie and Pagido are also relevant competitors in the employee wellness space, with Billie focusing on mental health support and Pagido offering financial wellness solutions. According to Growjo, HUMANOO’s market share in employee wellness is around 0.14%, indicating a competitive landscape with these players vying for market dominance. Billie and Pagido differentiate themselves through niche specialization, but HUMANOO’s broader platform aims to integrate multiple wellness aspects for a comprehensive approach (Growjo).

Alternatives

HUMANOO Alternatives

Product & Pricing

HUMANOO Product and Pricing Intelligence

As of April 2026, HUMANOO offers a range of product and pricing plans tailored to individual users and organizations. According to their official pricing page, HUMANOO provides different tiers, including free and paid options, with the paid plans offering additional features such as personalized coaching, advanced health analytics, and corporate wellness solutions (humanoo.com). The specific details of these tiers, including features and costs, are updated periodically, with the latest available information indicating a structured approach to accommodate both individual and enterprise needs.

Recent pricing changes or updates are reflected in their 2026 reviews, which highlight ongoing adjustments to their pricing strategy to stay competitive in the health and wellness tech market (OMR Reviews). The platform's free tier typically includes basic access to health and wellness content, while premium plans unlock comprehensive features such as personalized health programs, coaching, and corporate integrations. For organizations, HUMANOO offers tailored packages that include management tools and analytics, making it suitable for corporate wellness programs.

Overall, HUMANOO's pricing model emphasizes flexibility, with recent updates aimed at expanding access and enhancing feature sets to meet evolving customer demands in 2026 (humanoo.com). For the most current and detailed pricing information, visiting their official website or review sources is recommended.

Hiring & Layoffs

HUMANOO Hiring and Layoffs

As of April 2026, HUMANOO appears to be experiencing a phase of strategic growth, with recent hiring activities reflecting this trend. The company has notably expanded its team, including key executive appointments such as a new Chief Human Resources Officer (CHRO), indicating a focus on scaling operations and strengthening leadership during rapid growth phases (HR Chief Magazine).

Recent job openings, such as operations roles in Germany, suggest that HUMANOO is actively recruiting to support its expanding product offerings and market presence, particularly in the health and wellness sector (LinkedIn). The company's expansion into the U.S. market, highlighted by its Series A funding and scaling efforts, further underscores its growth strategy (Humand.co).

Regarding layoffs, there is no publicly available information indicating significant workforce reductions. Instead, the company's recent hiring patterns and leadership appointments signal a focus on scaling and innovation, likely driven by increased demand for AI-powered health and wellness solutions in 2026 (Programs.com). Overall, HUMANOO’s hiring trends suggest a strategic emphasis on strengthening leadership and expanding its global footprint to capitalize on emerging opportunities in health tech.

Leadership

HUMANOO Management and Leadership Team

The HumanOO Management and Leadership Team includes key executives and recent leadership changes, although specific details about the entire team are limited. As of late 2024, Denys Ivanchenko is a notable figure associated with the company, with his profile available on The Org, indicating his involvement in the organizational structure (The Org).

Recent updates suggest that Maximilien A. Notter, a co-founder, remains influential within the company, as evidenced by his LinkedIn activity from October 2024, which highlights ongoing leadership engagement (LinkedIn).

While detailed information about the entire board or additional C-suite hires is not explicitly available in the current search results, the company has been active in securing funding and expanding its leadership team, including recent funding rounds such as a $10 million Series B in August 2023, which often coincides with leadership growth (Humanoo).

Financials

HUMANOO Financial Performance, Fundraising, M&A

Humanoo has demonstrated notable financial activity and growth in recent years. As of the latest available data, Humanoo's revenue stands at approximately $6.6 million, reflecting its expanding digital health and wellness services (ZoomInfo). The company has also secured significant funding rounds, including a $10 million Series B financing round in August 2023, aimed at scaling its B2B digital wellness solutions (Humanoo).

Regarding valuation, specific post-money valuation figures are not explicitly detailed in the available sources, but the company's growth trajectory and funding activity suggest a strong valuation within the digital health sector (CB Insights). In terms of M&A activity, Humanoo was acquired by TELUS Health in a strategic transaction that involved a global process with both strategic and financial acquirers, indicating its valuable position in the health tech market (Lincoln International).

Overall, Humanoo's financial health appears robust, supported by consistent funding, strategic acquisitions, and steady revenue growth, positioning it as a significant player in the digital health industry as of 2026.

Partnerships

HUMANOO Partnerships, Clients and Vendors

HUMANOO has established a strong ecosystem of partnerships, clients, and technology integrations that underscore its position as a leading digital health platform. Notable enterprise clients include major organizations such as Decathlon, SCOR, Lenovo, die Mobiliar, Die Techniker, Hays, La Banque Postale, and NÜRNBERGER Versicherung, reflecting its widespread adoption across various industries (LinkedIn).

In terms of partnerships, HUMANOO has collaborated with significant entities like MAXIS Global Benefits Network, which partnered with HUMANOO to enhance employee wellbeing programs (covermagazine.co.uk). Additionally, the company was acquired by TELUS Health, a major player in health technology, further integrating HUMANOO's solutions into a broader health ecosystem (mainsights.io).

HUMANOO's technology ecosystem features integrations that support corporate health and wellbeing, serving over 1,000 organizations worldwide, which demonstrates its extensive ecosystem relationships and influence in the digital health space (humanoo.com). The company's recent funding rounds and investor backing, including Helsana, Sanitas, and Verve Ventures, highlight its strong financial position and growth trajectory as of 2026 (tracxn.com).

Events

HUMANOO Event Participations

HUMANOO has been actively involved in various events related to digital health and corporate wellness. Notably, they participated in the HumanX 2026 event, which is highlighted on their official resources and was published on May 26, 2022, indicating their engagement in significant industry gatherings (mofo.com). Additionally, HUMANOO has been featured in press releases and discussions surrounding digital health solutions, such as the Garmin Health Summit in 2023, which celebrates smartwatch-enabled digital health innovations (garmin.com). While specific details about conferences, trade shows, webinars, or community events they sponsor or attend are limited in the available results, their participation in prominent industry events like HumanX 2026 and their active press presence suggest ongoing engagement in the digital health and corporate wellness community (humanoo.com). For more detailed and updated information, visiting their official website or contacting them directly would be recommended.

Frequently Asked Questions

What does HUMANOO's acquisition by TELUS Health signal about its strategic trajectory and exit path?

HUMANOO's acquisition by TELUS Health marks a strategic exit rather than an independent growth story — the company was sold through a global process that included both strategic and financial acquirers, with Lincoln International advising. This suggests HUMANOO reached a scale attractive to a large health-tech consolidator but had not yet grown to standalone public-market viability. For corp-dev teams, the deal confirms that B2B digital wellness platforms with enterprise insurance and employer clients (Helsana, Sanitas, Die Techniker) are acquisition targets for large health-services players seeking distribution and product breadth.

What does HUMANOO's $10M Series B in August 2023 — followed relatively quickly by an acquisition — suggest about how the capital was deployed and why a sale made sense?

The rapid sequence of a $10M Series B in August 2023 and a subsequent acquisition by TELUS Health suggests the Series B was likely a growth-and-prove-it round rather than a long runway play, with revenue reported at approximately $6.6M at the time. At that revenue level, the capital was almost certainly needed to accelerate B2B sales and international expansion, but the company's investors — including Helsana, Sanitas, and Verve Ventures — appear to have concluded that a strategic acquirer could scale the platform faster than continued independent fundraising. The outcome is consistent with a controlled exit process rather than a distressed sale.

What does HUMANOO's enterprise client roster reveal about its go-to-market wedge and the segments where it has real traction?

HUMANOO's named clients — Decathlon, Lenovo, Hays, SCOR, La Banque Postale, NÜRNBERGER Versicherung, and Swiss insurers die Mobiliar and Die Techniker — reveal a dual-sided go-to-market that targets both large employers and insurance carriers. The insurance-carrier angle (Die Techniker, NÜRNBERGER, Helsana as investor) is particularly notable, as it suggests HUMANOO positioned its platform as a policyholder engagement tool, not purely a corporate HR benefit. This insurance distribution wedge differentiates it from pure-play corporate wellness vendors and likely made it attractive to TELUS Health, which operates in employer and payer health markets.

What does HUMANOO's partnership with MAXIS Global Benefits Network signal about its international expansion ambitions before the TELUS acquisition?

The MAXIS Global Benefits Network partnership — a network that connects multinational employers to local benefit plans across dozens of countries — signals that HUMANOO was actively pursuing multinational employer clients and cross-border distribution well before the TELUS acquisition. Partnering with MAXIS is a credible shortcut to enterprise multinationals without building a direct sales presence in each market. This move, combined with Series B funding earmarked for scaling B2B wellness, suggests HUMANOO's pre-acquisition strategy was to use channel partnerships to access global employers rather than organic country-by-country expansion.

With revenue around $6.6M and over 1,000 organizational clients, what does HUMANOO's implied average contract value suggest about its pricing power and competitive positioning?

If HUMANOO serves over 1,000 organizations at approximately $6.6M in revenue, the implied average contract value is roughly $6,600 per organization annually — a figure that points to predominantly SME clients or low per-seat pricing rather than large enterprise contracts. This is a meaningful competitive signal: it suggests HUMANOO competes on accessibility and breadth of wellness content rather than deep clinical integration or high-value analytics, which limits pricing power compared to more specialized or clinically oriented competitors. Scaling revenue will likely require either moving upmarket to larger accounts or significantly increasing per-seat monetization.

What does HUMANOO's competitive set — Deep Care, Uplyfe, RAYNY — reveal about where the market boundaries are being drawn and how differentiated HUMANOO's position actually is?

The competitive set around HUMANOO (Deep Care, Uplyfe, RAYNY, Billie, Pagido) is fragmented and largely niche-focused, which reflects the broader corporate wellness market's low consolidation. HUMANOO's 0.14% reported market share confirms it operates in a crowded field without dominant scale. Its differentiation appears to rest on breadth — combining fitness, nutrition, mental health, and insurance-carrier integration on one platform — rather than depth in any single category, which creates a risk of being outflanked by specialists on clinical depth or by HR-platform giants on distribution.

What does HUMANOO's participation in the Garmin Health Summit and HumanX signal about its technology integration strategy?

Participation in the 2023 Garmin Health Summit — an event specifically celebrating smartwatch-enabled digital health — indicates HUMANOO was actively pursuing wearable-device integration as a data input layer for its wellness programs, consistent with its platform's fitness and physical health focus. Engagement in events like HumanX further signals an intent to position within AI-driven health innovation conversations. Together these signal a product roadmap oriented toward connected-device data and potentially AI-personalized health interventions, both of which would have been strategically relevant to TELUS Health's broader health-data ambitions.

What does the involvement of Swiss insurance investors (Helsana, Sanitas) in HUMANOO's cap table signal about the company's product validation and distribution strategy?

Having Helsana and Sanitas — two of Switzerland's largest health insurers — as investors is a strong product-validation signal: these are strategic investors who would back HUMANOO only if they saw credible policyholder engagement value, not purely financial returns. It also implies embedded distribution, as insurer investors typically integrate portfolio-company tools into their own member offerings. This insurer-as-distribution-channel model is a defensible moat and likely one reason TELUS Health found HUMANOO attractive, since TELUS already operates across employer and payer segments and could extend HUMANOO's insurer partnerships into new markets.

What does the appointment of a new CHRO during a rapid growth phase — and the broader hiring pattern — suggest about HUMANOO's organizational priorities heading into the acquisition?

Appointing a Chief Human Resources Officer during a rapid growth phase typically signals that a company is scaling headcount quickly enough to require institutionalized people-operations, often a precursor to either a large funding round or an M&A process requiring clean organizational due diligence. Combined with active operations hiring in Germany, HUMANOO's pre-acquisition posture appears to have been one of deliberate infrastructure-building rather than cost-cutting — a profile consistent with a company being prepared for a strategic transaction. There are no signals of layoffs or workforce reduction in the available record.

What does the fact that co-founder Maximilien Notter remained publicly active on LinkedIn through October 2024 — referencing both HUMANOO and TELUS — suggest about post-acquisition leadership continuity?

Notter's continued public activity referencing both HUMANOO and TELUS Health through late 2024 suggests he remained engaged with the business post-acquisition, at least in an ambassadorial or transitional capacity, rather than departing immediately at close — a pattern common in founder-led acquisitions where the acquirer values continuity of client relationships and product vision. This is a positive signal for integration stability, though it does not confirm a formal ongoing executive role. ForesightIQ tracks leadership movement signals like this as an indicator of integration health in post-M&A situations.

Is HUMANOO's financial trajectory — ~$6.6M revenue, a $10M Series B, then an acquisition — a growth success story or a sign the standalone business hit a ceiling?

The trajectory is most accurately read as a contained success that hit a scaling ceiling rather than a breakout growth story. Revenue of approximately $6.6M after multiple funding rounds and nearly a decade of operation (founded 2016) implies modest organic growth, and the relatively rapid pivot from Series B to strategic sale suggests investors and founders concluded that independent scaling to meaningful market share would require capital and time that a strategic acquirer could more efficiently provide. The TELUS Health acquisition is a credible outcome for a niche B2B wellness platform with validated insurance-channel distribution, but it is not the trajectory of a company on a path to IPO or category leadership.

Powered by ForesightIQ · Competitive intelligence from digital exhaust